Our observations suggest that using mRNA CAR‐Ts to target BCMA can result in durable depletion of autoantibodies and clinically meaningful improvement in MG severity scores without severe toxicity, for example, agammaglobulinemia, or increased risk of infection. This evidence concerns the gene TNFRSF17 and agammaglobulinemia.